Nautilus Biotechnology, Inc. (NASDAQ:NAUT - Get Free Report) was down 3.2% during mid-day trading on Monday . The company traded as low as $0.79 and last traded at $0.80. Approximately 260,074 shares were traded during trading, a decline of 38% from the average daily volume of 417,342 shares. The stock had previously closed at $0.83.
Nautilus Biotechnology Price Performance
The firm has a market cap of $101.33 million, a PE ratio of -1.54 and a beta of 1.42. The business's fifty day moving average is $0.72 and its 200-day moving average is $0.76.
Nautilus Biotechnology (NASDAQ:NAUT - Get Free Report) last posted its earnings results on Thursday, July 31st. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.02. Analysts forecast that Nautilus Biotechnology, Inc. will post -0.57 EPS for the current year.
Insider Buying and Selling at Nautilus Biotechnology
In other Nautilus Biotechnology news, CEO Sujal M. Patel bought 116,500 shares of Nautilus Biotechnology stock in a transaction dated Friday, September 5th. The stock was purchased at an average price of $0.67 per share, for a total transaction of $78,055.00. Following the completion of the purchase, the chief executive officer directly owned 10,258,221 shares of the company's stock, valued at approximately $6,873,008.07. This trade represents a 1.15% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have bought a total of 220,000 shares of company stock valued at $147,635 in the last three months. 41.10% of the stock is owned by company insiders.
Hedge Funds Weigh In On Nautilus Biotechnology
Several large investors have recently modified their holdings of the business. Bank of America Corp DE increased its stake in shares of Nautilus Biotechnology by 37.1% in the fourth quarter. Bank of America Corp DE now owns 49,419 shares of the company's stock worth $83,000 after purchasing an additional 13,363 shares in the last quarter. Presidio Capital Management LLC increased its stake in shares of Nautilus Biotechnology by 246.6% in the second quarter. Presidio Capital Management LLC now owns 34,664 shares of the company's stock worth $25,000 after purchasing an additional 24,664 shares in the last quarter. Sentinel Trust Co. LBA grew its stake in Nautilus Biotechnology by 9.8% during the first quarter. Sentinel Trust Co. LBA now owns 280,000 shares of the company's stock valued at $241,000 after acquiring an additional 25,000 shares in the last quarter. Squarepoint Ops LLC purchased a new position in Nautilus Biotechnology during the fourth quarter valued at approximately $44,000. Finally, XTX Topco Ltd grew its stake in Nautilus Biotechnology by 86.2% during the second quarter. XTX Topco Ltd now owns 66,194 shares of the company's stock valued at $48,000 after acquiring an additional 30,641 shares in the last quarter. Hedge funds and other institutional investors own 50.71% of the company's stock.
Nautilus Biotechnology Company Profile
(
Get Free Report)
Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Nautilus Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nautilus Biotechnology wasn't on the list.
While Nautilus Biotechnology currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
